Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
December 04, 2024 08:00 ET
|
Solid Biosciences Inc.
- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Upcoming Investor Conferences
November 26, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences to Present at the Jefferies London Healthcare Conference
November 14, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 06, 2024 16:05 ET
|
Solid Biosciences Inc.
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
October 31, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:15 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
September 12, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...